Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $56,548.80 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 2,380 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $23.76, for a total transaction of $56,548.80. Following the completion of the transaction, the insider directly owned 66,345 shares of the company’s stock, valued at $1,576,357.20. The trade was a 3.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 3.4%

NASDAQ:KMTS opened at $25.06 on Thursday. The company has a market cap of $1.47 billion, a PE ratio of -10.36 and a beta of 0.58. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The company’s 50 day moving average is $22.78 and its two-hundred day moving average is $22.52.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The company had revenue of $28.64 million during the quarter. Analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on KMTS shares. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. The Goldman Sachs Group reduced their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. BTIG Research lifted their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kestra Medical Technologies has a consensus rating of “Hold” and an average target price of $27.83.

Hedge Funds Weigh In On Kestra Medical Technologies

Several large investors have recently made changes to their positions in KMTS. Price T Rowe Associates Inc. MD increased its stake in shares of Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after purchasing an additional 2,529,851 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Kestra Medical Technologies by 180.8% in the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after buying an additional 612,343 shares in the last quarter. Millennium Management LLC purchased a new position in Kestra Medical Technologies during the first quarter valued at $11,036,000. Brown Advisory Inc. lifted its position in shares of Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after acquiring an additional 428,996 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC acquired a new stake in shares of Kestra Medical Technologies in the fourth quarter worth approximately $9,282,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.